DC Field | Value | Language |
---|---|---|
dc.contributor.author | 한지원 | ko |
dc.contributor.author | 박수형 | ko |
dc.date.accessioned | 2021-12-14T06:45:18Z | - |
dc.date.available | 2021-12-14T06:45:18Z | - |
dc.date.created | 2021-12-13 | - |
dc.date.created | 2021-12-13 | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Journal of Liver Cancer, v.21, no.2, pp.139 - 145 | - |
dc.identifier.issn | 2288-8128 | - |
dc.identifier.uri | http://hdl.handle.net/10203/290571 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is the fifth most common cancer, and the second leading cause of cancer-related death worldwide. Although recent advances in immune checkpoint inhibitor-based immunotherapy have initiated a new era for advanced HCC treatment, the majority of HCC patients receiving immune checkpoint blockades do not derive clinical benefit. Thus, there remains an urgent need for novel immunotherapeutic strategies with improved therapeutic efficacy. Here we review recent studies of immune checkpoint blockade in HCC, providing the necessary basis for the rational design of immunotherapy. | - |
dc.language | English | - |
dc.publisher | 대한간암학회 | - |
dc.title | Advances in immune checkpoint inhibitors for hepatocellular carcinoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.citation.volume | 21 | - |
dc.citation.issue | 2 | - |
dc.citation.beginningpage | 139 | - |
dc.citation.endingpage | 145 | - |
dc.citation.publicationname | Journal of Liver Cancer | - |
dc.identifier.kciid | ART002759300 | - |
dc.contributor.localauthor | 박수형 | - |
dc.contributor.nonIdAuthor | 한지원 | - |
dc.description.isOpenAccess | Y | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Immune checkpoint inhibitors | - |
dc.subject.keywordAuthor | PD-1-PD-L1 blockade | - |
dc.subject.keywordAuthor | Immunotherapy | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.